Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.

Background: Cryptococcal meningoencephalitis is a lethal infection with relatively few therapeutic options. The optimal dosage of liposomal amphotericin B (LAmB) alone or in combination with flucytosine is not known.Methods: A murine model of cryptococcal meningoencephalitis was used. The fungal den...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Infectious Diseases Vol. 208; no. 2; pp. 351 - 362
Autores principales: O'Connor, Lucy, Livermore, Joanne, Sharp, Andrew D, Goodwin, Joanne, Gregson, Lea, Howard, Susan J, Felton, Timothy W, Schwartz, Julie A, Neely, Michael N, Harrison, Thomas S, Perfect, John R, Hope, William W
Formato: research Journal Article
Publicado: Oxford University Press / USA Jul2013
Acceso en línea:Ver este registro en EBSCOhost
Descripción
Sumario:Background: Cryptococcal meningoencephalitis is a lethal infection with relatively few therapeutic options. The optimal dosage of liposomal amphotericin B (LAmB) alone or in combination with flucytosine is not known.Methods: A murine model of cryptococcal meningoencephalitis was used. The fungal density in the brain was determined using quantitative cultures. Pharmacokinetic-pharmacodynamic relationships were determined for LAmB and flucytosine administered alone. The effect of the combination was described using the Greco model and a mathematical model. The results were bridged to humans.Results: Inoculation resulted in hematogenous dissemination and logarithmic growth within the central nervous system. There was histological evidence of multifocal infection throughout the brain. Both LAmB and flucytosine produced a dose-dependent reduction in fungal burden. The effect of the combination of agents in the brain was additive. Bridging studies suggested that a human dosage of LAmB 3 mg/kg/d resulted in a submaximal antifungal effect. Regimens of LAmB 6 mg/kg/d alone, LAmB 3 mg/kg/d plus flucytosine 50 mg/kg/d, and LAmB 3 mg/kg/d plus flucytosine 100 mg/kg/d all resulted in near-maximal antifungal activity.Conclusions: Potential regimens for further study in clinical trials include LAmB 6 mg/kg/d alone, LAmB 3 mg/kg/d plus flucytosine 50 mg/kg/d, and LAmB 3 mg/kg/d plus flucytosine 100 mg/kg/d.